Skip to main content
. 2022 Apr 4;13:796508. doi: 10.3389/fimmu.2022.796508

Figure 5.

Figure 5

Associations between B cell alterations and flare development. The forest plots illustrate results from proportional hazards (Cox) regression analysis, investigating associations between rapid or early relative to baseline percentage changes in selected B cell and plasma cell subsets and development of the first SFI flare of any severity (mild/moderate or severe; (A) or the first severe SFI flare (B) occurring from week 24 through week 76 or the last available follow-up visit. All models included belimumab use (any dose) as a covariate, and the result for the respective model is plotted in terracotta colour. The potential interaction between cell alterations and belimumab use were accounted for. Additionally, all models were adjusted for age, sex, ethnicity, SLE disease duration, use of methotrexate, use of azathioprine, use of mycophenolate mofetil, use of immunosuppressants other than those mentioned before, and the BLISS study to account for batch variations in cell analyses. One set of models investigating associations between early B cell changes and flare development was also adjusted for the relative to baseline cell alterations from baseline through week 8 to account for alterations in opposing directions in the rapid and early follow-up phase. Circles denote hazard ratios and whiskers denote 95% confidence intervals. Statistically significant associations are indicated with asterisks. SFI, Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) - Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Flare Index.

HHS Vulnerability Disclosure